The estimated Net Worth of Lp22 Nw Fund, Lp22 Nw Fund ... is at least $18.8 millió dollars as of 15 April 2019. Lp22 Fund owns over 66,760 units of Merrimack Pharmaceuticals Inc stock worth over $18,789,886 and over the last 6 years Lp22 sold MACK stock worth over $0.
Lp22 has made over 2 trades of the Merrimack Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Lp22 bought 66,760 units of MACK stock worth $391,214 on 15 April 2019.
The largest trade Lp22's ever made was buying 82,873 units of Merrimack Pharmaceuticals Inc stock on 5 April 2019 worth over $496,409. On average, Lp22 trades about 74,817 units every 5 days since 2019. As of 15 April 2019 Lp22 still owns at least 1,241,896 units of Merrimack Pharmaceuticals Inc stock.
You can see the complete history of Lp22 Fund stock trades at the bottom of the page.
Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy és Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include: